Health

FDA Approves Keytruda (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy

DailyTrendDailyTrend
Jun 14, 2025 - 16:00
 0  0
FDA Approves Keytruda (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy
RAHWAY, N.J.--(BUSINESS WIRE) June 13, 2025 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), Merck’s...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

A New Way to Reduce Children’s Deaths: Cash

A New Way to Reduce Children’s Deaths: Cash

DailyTrend Aug 18, 2025  0  0

A $45 Treatment Can Save a Starving Child. US Aid Cuts Have Frozen the Supply

A $45 Treatment Can Save a Starving Child. US Aid Cuts ...

DailyTrend Aug 16, 2025  0  0

How Medicaid Cuts Could Force Disabled Americans Into Institutions

How Medicaid Cuts Could Force Disabled Americans Into I...

DailyTrend Aug 20, 2025  0  0

FDA Approves Tonmya (cyclobenzaprine hydrochloride sublingual tablets) for the Treatment of Fibromyalgia

FDA Approves Tonmya (cyclobenzaprine hydrochloride subl...

DailyTrend Aug 16, 2025  0  0

A 1990 Measles Outbreak Shows How the Disease Can Roar Back

A 1990 Measles Outbreak Shows How the Disease Can Roar ...

DailyTrend Aug 21, 2025  0  0

Hiker in Tennessee Who Picked Up a Venomous Snake Dies After Being Bitten

Hiker in Tennessee Who Picked Up a Venomous Snake Dies ...

DailyTrend Aug 17, 2025  0  0